Heparanase-neutralizing antibodies have been suggested for the treatment of diffuse non-Hodgkin’s B-cell and follicular lymphomas [17] through the inhibition of cell invasion and tumor metastasis processes [17,18,19]. Here, HPSE is linked to neoplasm.